Implications of MicroRNAs in the Vascular Homeostasis and Remodeling by Lee, Seahyoung et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 3
Implications of MicroRNAs in the Vascular Homeostasis
and Remodeling
Seahyoung Lee, Eunhyun Choi, Min-Ji Cha and
Ki-Chul Hwang
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/60740
Abstract
Vascular remodeling or arterial remodeling is a process of adaptive alteration of
vascular wall architecture and leads to the endothelial cell (EC) dysfunction and
synthetic or contractile phenotypic change of VSMCs, and the infiltration of mono‐
cytes and Macrophages that promotes vascular diseases including atherosclerosis.
Recent findings have demonstrated that microRNAs (miRNAs) are involved in
regulating gene expression at posttranscriptional level and disease pathogenesis. A
change of miRNA expression profiles plays key roles in the gene expressions and the
regulation of cellular functions. In this chapter, we summarize the vascular remodel‐
ing-related miRNAs and their functions in vascular biology.
Keywords: Vascular remodeling, vascular homeostasis, smooth muscle cells, endo‐
thelial cells, macrophage, microRNAs, vascular smooth muscle cell phenotypic
switch
1. Introduction
Vascular remodeling (or arterial remodeling) is a process of adaptive alteration of vascular
wall architecture and is caused by variety of environmental stimuli such as oxidative stress,
vascular injury, and hemodynamic stress [1]. Endothelial cells (ECs) and vascular smooth
muscle cells (VSMCs) compose the arteries and play critical roles in vascular remodeling in
conjunction with inflammatory cells such as monocytes or macrophages [2]. During vascular
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remodeling, the EC dysfunction, synthetic or contractile phenotypic change of VSMCs, and
the infiltration of monocytes and macrophages promote vascular diseases including athero‐
sclerosis [3, 4]. Therefore, modulation of VSMC phenotype, maintenance of ECs, and regula‐
tion of inflammation in the vessel wall are important in arterial function and homeostasis.
Recent findings have been demonstrated that microRNAs (miRNAs) are involved in regulat‐
ing gene expressions at posttranscriptional level and disease pathogenesis [5, 6]. Importantly,
altered specific set of miRNAs is closely related to cell fate determination, tissue function, and
homeostasis [7, 8], indicating that miRNAs plays key roles in the gene expressions and the
regulation of cellular functions [9]. Consequently, the change of miRNA expressions can lead
to VSMC phenotype switch, EC dysfunction, and the inflammatory response and lipid
accumulation of macrophage in vascular pathophysiology [10–12].
In this chapter, we summarize the vascular remodeling-related miRNAs and the function of
these miRNAs in vascular biology, and suggest novel therapeutic strategies for the treatment
and/or prevention of vascular diseases via controlling the expressions of miRNA regulation.
2. MicroRNAs
MicroRNAs (miRNAs or miRs) are small noncoding RNA molecules approximately 18–25
nucleotides in length that participate in controlling gene expression at the posttranscriptional
level [13]. MicroRNAs directly bind to 3 untranslated regions (3UTR) of target mRNAs, leading
to translational inhibition and/or mRNA degradation [9]. One miRNA can suppress multiple
target protein-coding mRNAs, which also means that a single protein can be regulated by
numerous miRNAs [14]. Interestingly, about two-thirds of the coding-mRNA genes are
regulated by miRNAs [15]. Since the first discovery of miRNAs in Caenorhabditis elegans in
1993, more than 1800 miRNAs in human have been identified and recorded in miRBase 21
(www.mirbase.org) [16].
The biogenesis of miRNAs are initiated by transcription from their genes by RNA polymerase
II, which produces primary miRNAs (pri-miRNAs) with hundreds to thousands of nucleotides
and single or multiple stem-loop-like structures [17]. After transcription, the pri-miRNAs are
cleaved at ~70-nucleotide hairpin-shaped precursor miRNA (pre-miRNA) by RNase-III
endonuclease (Drosha) and DiGeorge syndrome Critical Region 8 protein (DGCR8) complex
[18]. The pre-miRNAs are transferred from nuclear to cytoplasm through the nuclear export
protein exportin-5 [19]. In the cytoplasm, the pre-miRNAs are processed to produce mature
miRNA duplex mediated by RNase-III endonuclease, Dicer: the passenger strand and the
guide strand (~22 nucleotides long) [20]. The guide strand is loaded to RNA-induced silencing
complex (RISC), and the passenger strand is degraded [21]. The miRNA–RISC complex
recognizes and binds the miRNA based on the complementary match between the miRNA
seed sequence (2–8 nucleotides in the 5' end) and the 3 UTR of the target mRNA, and this
results in translational suppression and/or mRNA degradation (Figure 1) [22, 23].
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Figure 1. The biogenesis of miRNAs.
Increasing evidence suggests that miRNAs play important roles in a wide range of biological
functions and processes, including but not limited to, development, growth, pathophysiology,
regeneration, inflammation, stem cell fate regulation, and aging [24–29]. Because the changes
of miRNA expression profiles are related to various human diseases, such as cardiovascular
diseases, cancer, neuropathy, infection, and metabolic disorders [9, 30–34], the modulation of
miRNA expressions consider as a novel therapeutic target and may inspire a new strategy for
treatment of these diseases [35–37].
3. Vascular smooth muscle cells
The VSMCs of  blood vessels  in adult  generally show a low proliferation rate and well-
maintained homeostasis [38]. However, upon external stimuli, such as cytokines, blood flow
rates, shear stress, hormones, injury, and inflammation, provoke the phenotypic switch of
VSMCs from contractile to synthetic [2, 39]. The contractile or differentiated VSMCs express
contractile markers, smooth muscle myosin heavy chain (SM-MHC), alpha smooth muscle
actin (SM α-actin),  and calponin; whereas the synthetic or dedifferentiated VSMCs show
an increase of  cell  proliferation,  migration,  upregulation of  extracellular matrix proteins,
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such as collagen, elastin, and proteoglycans, and a decrease in the expression of contrac‐
tile  markers  [16,  40].  The  plasticity  of  VSMCs  plays  important  roles  in  the  vascular
development and pathological/physiological  vascular  remodeling.  The contractile  pheno‐
type  is  required  to  maintain  the  normal  arterial  wall  structure  and  function,  while  the
synthetic  phenotype  is  involved  in  the  development  of  atherosclerosis,  restenosis  after
angioplasty, and hypertension [1, 39, 41].
The recent studies show that the regulation of VSMC phenotypic change is associated with the
alteration of local environment as well as the modulation of gene expressions by miRNAs.
Albinsson et al. reported that VSMC-specific deletion of Dicer-induced embryonic lethality at
embryonic days 16 to 17 due to the thin and hypotensive vessel walls, impaired contractility,
and hemorrhage [42]. In addition, the loss of Dicer in VSMCs of adult mice also showed a
dramatic decrease in blood pressure, the impairment of contractile function, morphology, and
phenotypic modulation [43]. These results strongly suggest that miRNAs are essential to
vascular development and keep a balance of VSMC phenotype (Figure 2).
3.1. miRNAs in the contractile phenotype of VSMCs
3.1.1. miR-143 and miR-145
MiR-143 and miR-145 are the most well-known and enriched miRNAs in VSMCs and are in a
bicistronic miRNA cluster on human chromosome 5 [44]. The significant role of miR-143 and
miR-145 is to drive VSMC development and differentiation from human embryonic stem cells
via targeting the stem cell pluripotency factors OCT4 (octamer-binding transcription factor 4),
SOX2 [SRY (sex-determining region Y)-box 2], and KLF4 (Krüppel-like factor 4) [45]. After
VSMC development, miR-143 and miR-145 are required for maintaining homeostasis of
VSMCs through the suppression of multiple target proteins, such as KLF4, KLF5, E twenty-
six (ETS)-like transcription factor 1 (ELK1), versican, several actin remodeling proteins, and
angiotensin-converting enzyme. The transcriptional activation of miR-143 and miR-145 also
leads to the expression of contractile genes [41, 46–48].
The maintenance of the VSMC contractile phenotype is modulated by several signaling
pathways including serum response factor (SRF)/myocardin, transforming growth factor β
(TGF-β), bone morphogenetic proteins 4 (BMP4), and Jagged-1 (Jag-1)/Notch signaling, which
regulates the expression of miR-143 and miR-145 (Figure 3) [46]. The promoter region of
miR-143 and miR-145 represents highly conserved cis elements and potential binding sites
containing CArG box of SRF and Nkx2.5. In addition, myocardin and myocardin-related
transcription factor A (MRTF-A), cofactors of SRF, synergistically and strongly activate the
miR-143 and miR-145 transcription [49, 50]. The upregulation of miR-143 and miR-145 by TGF-
β and BMP4 mediates the induction of SRF cofactors: TGF-β upregulates myocardin via the
activation of parallel pathways of p38MAPK and SMAD dependent [51], whereas BMP4
stimulates the nuclear translocation of MRTF-A [52]. The Jag-1-mediated activation of Notch
receptors is also activating miR-143 and miR-145 transcription [46]. Activation of Notch
receptor by Jag-1 results in proteolytic cleavage and translocation to the nucleus of the Notch
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intracellular domain (NICD). In the nucleus, NICD forms complex with C promoter binding
factor 1 (CBF1), which is binding to miR-143 and miR-145 promoter and increases in miR-145
and miR-145 expression [46].
Figure 2. miRNAs in phenotypic switch of VSMCs.
The expression levels of miR-143 and miR-145 significantly decrease in animal vascular
diseases models including apolipoprotein E knockout mice (ApoE–/–), carotid artery ligation
injury models, carotid balloon injury models, and in aortas from patients with aortic aneurism
[53, 54]. MiR-143 and miR-145 knockout murine VSMCs showed a shift from contractile to
synthetic state and the development of neointimal lesions [55], whereas the VSMC-specific
overexpression of miR-143 and 145 increased the plaque stability and the expression of
contractile proteins, and decreased macrophage infiltration, the expression of KLF4 and KLF5,
and neointimal lesion formation [54, 56]. Altogether, these data indicate that miR-143 and
miR-145 play an important role in the VSMC homeostasis and strengthen the VSMC contractile
phenotype.
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Figure 3. The signaling pathway of miR-143 and miR-145 expression.
3.1.2. miR-1 and miR-133
Similar to miR-143 and miR-145, miR-1 and miR-133 are also in bicistronic miRNA clusters
and are induced by myocardin in VSMCs [57]. During differentiation of mouse ESC to VSMCs,
the expression level of miR-1 is gradually increased, which results in the upregulation of
VSMC-specific contractile proteins by repressing KLF4 [58]. Chen et al. demonstrated that
overexpression of myocardin in VSMCs increased miR-1 expression and inhibited VSMC
proliferation, which mediated the repression of Pim-1, a serine/threonine kinase [59].
The expression level of miR-133 is downregulated in proliferating VSMCs and after vascular
injury. Overexpression of miR-133 reduces VSMC growth, but the downregulation of miR-133
induces VSMC proliferation in vitro [57]. Both the transcription factor Sp-1 (specificity protein
1) which regulates VSMC phenotypic switch and the actin-binding protein moesin that
modulates VSMC migration are direct targets of miR-133. Accordingly, miR-133 overexpres‐
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sion in the rat carotid artery reduced neointimal hyperplasia, whereas anti-miR-133 increased
VSMC proliferation and neointimal formation after balloon injury [57].
3.1.3. miR-21
The expression of miR-21 mediates TGF-β and BMP4 signaling pathway and promotes the
contractile phenotype of VSMCs via downregulating programmed cell death 4 (PDCD4), a
negative regulator of smooth muscle contractile genes [60]. Another target of miR-21 is the
family of the dedicator of cytokinesis (DOCK) proteins, which promote VSMC migration by
modulating the activity of small Rac1 GTPase [61]. On the other hand, Horita et al. reported
that Fos-related antigen (FRA)-1, a direct target of miR-143, was a positive regulator of
increased miR-21 expression [62]. The upregulation of miR-143 by SRF repressed FRA-1
expression, which led to the decrease of VSMC proliferation via the repression of miR-21 and
subsequent increase of phosphatase and tensin homolog (PTEN), one of the target proteins of
miR-21 [62]. The dual function of miR-21 in promoting both contractile and synthetic pheno‐
type of VSMCs may suggest that diverse targets of miR-21 are involved in different biological
processes depending on the cellular environments or context.
3.1.4. Other miRNAs
Our group has reported that miR-29b and miR-365 inhibit the proliferation and migration of
VSMCs [63, 64]. The interleukin-3 (IL-3) is known to stimulate proliferation and migration in
vascular diseases, and it downregulates miR-29b expression. Mir-29b significantly decreases
the proliferation and migration of VSMCs through the inhibition of the signaling pathway
related to Mcl-1 (myeloid cell leukemia 1) and MMP2 (matrix metallopeptidase 2). Consistent
with the declined miR-29b expression in balloon-injured rat carotid arteries, overexpression
of miR-29b by local oligonucleotide delivery can inhibit neointimal formation [64]. The
proliferation of VSMCs by various stimuli, including platelet-derived growth factor (PDGF)-
BB, angiotensin II (Ang II), and serum, led to the downregulation of miR-365 expression levels.
The cell-cycle-specific cyclin D1 was found to be a potential target of miR-365; thus exogenous
miR-365 overexpression reduced VSMC proliferation and proliferating cell nuclear antigen
(PCNA) expression, blocking transition of G1/S [63, 65].
Li et al. reported that miR-663 is related to human VSMC phenotypic switch and the devel‐
opment of neointimal formation [66]. According to this particular study, overexpression of
miR-663 upregulated VSMC differentiation marker genes and inhibited PDGF-induced VSMC
proliferation and migration via targeting the transcription factor JunB and myosin light chain
9 (MYL9). Overexpression of miR-663 also dramatically attenuated the neointimal lesion
formation in mice after carotid artery ligation [66]. In addition, the same group identified that
miR-638 also is markedly downregulated by PDGF-stimulated human VSMCs, whereas
upregulated in human VSMCs cultured in differentiation medium, a condition that inhibits
proliferation [67]. Furthermore, the orphan nuclear receptor NOR1 (neuron-derived orphan
receptor 1) was identified as a target of miR-638 and downregulation of NOR1 was implicated
in the miR-638-mediated inhibitory effects on cyclin D1 expression, cell growth, and migration
of PDGF-induced VSMCs.
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3.2. miRNAs in the synthetic phenotype of VSMCs
3.2.1. miR-221 and miR-222
Similar to TGF-β and BMP4 promote VSMC contractile phenotype, PDGF induces VSMC
phenotype switch from contractile to synthetic type [41]. Mir-221 and miR-222 are well
characterized in VSMC phenotype switch and clustered on the X chromosome, and have same
seed sequence [68]. Mir-221 and miR-222 are transcriptionally induced by activating PDGF
pathway, which reduces the expression of contractile genes and promotes VSMC proliferation
and migration [69]. In addition, the expression of miR-221 and miR-222 are elevated in
neointimal lesion from balloon-injured rat carotid arteries [70]. The targets of miR-221 and
miR-22 include p27Kip1 and p57kip2, both of which are a negative regulator of VSMC proliferation
[70, 71]. Interestingly, miR-221 decreased the expression of c-kit, and this reduced c-kit
expression subsequently repressed the expression of a VSMC-specific nuclear coactivator
myocardin [69]. As the PDGF-treatment stimulated phenotype change of VSMCs, overexpres‐
sion of miR-221 and miR-222 accelerated VSMC proliferation and migration, while downre‐
gulation of them attenuated VSMC proliferation and neointimal formation in rat carotid artery
after angioplasty [70]. These data indicate that miR-221 and miR-222 have a crucial role in
regulating VSMC phenotype change, and suggest their therapeutic potential in pathological
vascular remodeling.
3.2.2. miR-146a
Recent study has shown that miR-146a is upregulated in rat balloon-injured arteries and
serum-induced proliferative VSMCs [72, 73]. KLF4, a negative regulator of VSMC prolifera‐
tion, was downregulated by miR-146a, and in turn, KLF4 repressed miR-146a expression
through binding to CACCC (or GGGTG) elements on the miR-146a promoter. This negative
feedback regulatory network between miR-146a and KLF4 regulates transcription of each
other, controlling VSMC proliferation in vitro and vascular neointimal hyperplasia in vivo [72].
Dong et al. demonstrated that miR-146a upregulation is related to the downregulation of
critical transcriptional factors such as the protein expression of nuclear factor-κBp65 (NF-
κBp65) and PCNA. In contrast, miR-146a knockdown is linked to the increase in pro-apoptotic
protein Bax expression [73]. Therefore, miR-146a is a novel regulator of VSMC proliferation in
cardiovascular diseases.
3.2.3. miR-24
Both TGF-β and BMP4 signaling are important in maintaining the VSMC contractile pheno‐
type, whereas PDGF signaling pathways can promote the synthetic phenotype conversion of
VSMCs. Although these signaling pathways play key roles in VSMC phenotypic changes, the
crosstalk between these pathways is not elucidating until quite recently. Chan et al. reported
that despite of BMP4 stimulation, the contractile genes are downregulated by co-treatment
with PDGF in human primary pulmonary SMCs (PASMCs) [74]. Furthermore, PDGF stimu‐
lation decreases the expression of Tribbles-like protein-3 (Trb3), an important modulator of
the BMP and TGF-β signaling pathway. Interestingly, the result of Trb3 promoter-luciferase-
Muscle Cell and Tissue62
reporter assay showed that the downregulation mechanism of Trb3 expression by PDGF is
associated with the effect of PDGF-induced miR-24, directly targeting 3URT of Trb3 mRNA,
rather than PDGF stimulation [74]. The knockout endogenous miR-24 by antisense oligonu‐
cleotides restored Trb3 expression as well as attenuates PDGF-mediated synthetic activity,
suggesting that PDGF-induced miR-24 expression which downregulated Trb3, and this
miR-24-mediated downregulation of Trb3 is sufficient to induce synthetic phenotypic changes
of VSMCs [74].
3.2.4. miR-26a
Leeper et al. demonstrated that serum-starved human aortic SMCs upregulates the expression
of contractile marker genes, and miR-26a is significantly downregulated during serum-
starvation and in murine abdominal aortic aneurysm (AAA) development models [75].
Overexpression of miR-26a promoted VSMC proliferation and migration as well as inhibited
apoptosis, whereas downregulation of miR-26a induced contractile gene expression and
reduced proliferation and migration. The potential targets of miR-26a include SMAD1 and
SMAD4, members of TGF-β and BMP superfamily downstream signaling cascade. Consis‐
tently, knockdown of miR-26a led to SMAD1 and Samd4 upregulation and activates TGF-β
and BMP signaling pathway. Thus, miR-26a is expected to actively participate in the regulation
of VSMCs as an enhancer of cell growth and migration, and an inhibitor of apoptosis, modu‐
lating TGF-β and BMP signaling [75].
3.2.5. miR-31
Although miR-31 plays an important role in cancer cell growth and proliferation [76–78], the
biological function of miR-31 in VSMCs remains unclear. Recently, Liu et al. found that miR-31
was an abundant miRNA in VSMCs of vascular walls, and was significantly upregulated in
proliferative VSMCs and rat carotid arteries with neointimal growth after balloon injury [79].
The serum- or PDGF-induced VSMC proliferation is inhibited by miR-31 inhibitor, 2′OMe-
miR-31 (the antisense oligonucleotide for miR-31 that is modified at each nucleotide by an O-
methyl moiety at the 2′-ribose position). On the contrary, overexpression of miR-31 using the
adenoviruses expressing rat miR-31 promotes VSMC proliferation [79]. The pro-proliferative
effect of miR-31 is mediated by the direct inhibition of the large tumor suppressor homolog 2
(LATS2) expression, and is accelerated by the activation of mitogen-activated protein kinase/
extracellular regulated kinase (MAPK/ERK) [79].
4. Endothelial cells
Vascular endothelial cells (ECs) cover the internal surface of blood vessels. The primary role
of ECs is the maintenance of vessel wall permeability and function as a sensor for the altered
physical and chemical signals by physiological or pathological processes including thrombo‐
sis, inflammation, and vascular wall remodeling [80–82]. The knockdown of Dicer in human
ECs resulted in the change of several key regulator proteins of EC biology and angiogenesis,
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such as TEK (Tie-2), KDR (VEGFR2), adhesion molecules and proteins, cytokine, chemokine,
and IL-8. Furthermore, EC-specific knockdown of Dicer activated the endothelial nitric oxide
synthase (eNOS) pathway, which reduces proliferation and capillary formation of EC, and the
endogenous miRNA expression levels were also significantly altered [83]. These results
indicate that altered miRNA expression in ECs affects the maintenance and functions of ECs
(Figure 4).
Figure 4. miRNAs in ECs regulating during vascular remodeling.
4.1. miR-126
Adhesion molecules in ECs are directly associated with leukocyte trafficking to the region of
the injury and/or inflammation [84]. Generally, resting ECs do not express adhesion molecules,
but activated ECs express adhesion molecules such as vascular cell adhesion molecule 1
(VCAM-1), which plays an important role in modulating leukocyte trafficking and inflamma‐
tion [85]. Based on microarray and Northern analysis, Harris et al. showed that miR-126 is the
most frequently expressed in HUVECs as well as other origin ECs from dermal, brain, and
vein [86]. In silico analysis suggests that VCAM-1 is one of the targets of miR-126. The upre‐
gulation of miR-126 by transfection of pre-miR-126 results in inhibiting TNF-α induced
VCAM-1 expression, whereas the knockdown of miR-126 by antisense miR-126 oligonucleo‐
tide is causing TNF-α induced VCAM-1 upregulation in a dose-dependent manner. In
addition, overexpression of miR-126 mediated a decrease of VCAM-1 downregulating
leukocyte adherence to ECs. These data suggest that miR-126 regulates the expression of
adhesion molecules and plays a crucial role in the control of vascular inflammation [86].
Fish et al. found that EC-specific miRNA miR-126 is also highly enriched in Flk-1 positive
vascular progenitors from differentiating mouse embryonic stem cells in the embryonic body
[87]. Nevertheless, overexpression of miR-126 using miR-126 mimic does not promote
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endothelial differentiation of embryonic stem cells. The loss-of-function of miR-126 by a
morpholino antisense to miR-126 shows that the EC migration and the formation/stability of
capillary tubes are decreased compared to normal HUVECs. In addition, EC-targeted deletion
of miR-126 results in vascular abnormalities such as vascular leakage, hemorrhaging, and
embryonic lethality in both zebrafish [87] and mice [88], because of reduced EC growth,
sprouting, and adhesion by decrease in angiogenic growth factor signaling. The pro-angio‐
genic function of miR-126 was due to its ability to repress two negative regulators of angiogenic
process, namely sprouty-related EVH1 domain-containing protein 1 (SPRED1) and phosphoi‐
nositol-3 kinase regulatory subunit 2 (PIK3R2) [87, 88]. Taken together, miR-126 is considered
as new therapeutic implication for modulating vascular formation, function, leakage, and
abnormal angiogenesis.
4.2. Endothelial Shear Stress (ESS) and miRNAs
The atherosclerotic lesions form at specific arterial regions such as the vicinity of branch points,
the outer wall of bifurcations, and the inner wall of curvatures, where they show the disturbed
flow and the change of hemodynamic forces, especially endothelial shear stress (ESS) [89]. ESS
has been reported to regulate endothelial gene expression and promotes EC activation and
atherosclerotic plaque progression and vascular remodeling [90, 91].
By miRNA microarray analysis using human umbilical vein endothelial cells (HUVECs), Ni
et al. identified that the expression of miR-663 was mediated by low ESS (LSS) and LSS-induced
miR-663 expression improved monocyte adhesion to ECs, but it had no effect on EC apoptosis.
MicroRNA-663 has been reported to regulate several transcription factors related to inflam‐
matory responses, such as KLF4, C/EBPB, and ATF3 [92].
In addition, miR-21 was also upregulated by LSS at transcriptional level in HUVECs through
an increased activity and binding of c-Jun, a component of transcription factor activator
protein-1 (AP-1), to the promoter region of miR-21 [93]. Mir-21 upregulated the expression of
VCAM-1 and monocyte chemotactic protein-1 (MCP-1) by suppressing the peroxisome
proliferators-activated receptor-α (PPARα), increasing adhesion of monocytes to ECs and pro-
inflammatory responses [93].
MicroRNA-92a, a member of miR-17~92 cluster, was upregulated by LSS in HUVECs [94]. The
decreased expression of miR-92a was correlated to the upregulation of KLF2 and subsequent
KLF2-mediated eNOS and thrombomodulin (TM) expression and NO production, all of which
are considered as potent anti-thrombotic, anti-adhesive, and anti-inflammatory properties [94,
95]. Therefore, LSS-induced miR-92a inhibited KLF2-mediated eNOS and TM expression that
resulted in impaired EC functions.
In contrast to LSS, high ESS (HSS) appears to be protective against atherosclerosis, but the
precise functions still remain unclear [96]. Mir-10a is one of the flow-induced miRNAs in ECs
and is known to be downregulated in athero-susceptible regions of the inner aortic arch and
aorto-renal branches than other regions [97]. The knockout of miR-10a led to IκB/NF-κB-
mediated inflammation, which suggested anti-inflammatory role of miR-10a. Interestingly,
two key regulators of IκBα degradation, mitogen-activated kinase kinase kinase 7 (MAP3K7;
Implications of MicroRNAs in the Vascular Homeostasis and Remodeling
http://dx.doi.org/10.5772/60740
65
TAK1) and β-transducin repeat-containing gene (β-TRC), are putative targets of miR-10a [97].
Therefore, miR-10a contributes to anti-inflammatory endothelial phenotype through the
inhibition of pro-inflammatory molecules in athero-susceptible regions.
In addition, Qin et al. found that laminar shear stress induced miR-19a that suppressed cyclin
D1 expression, leading to an arrest of cell cycle at G1/S transition [98]. Similar research by Chen
et al. showed that miR-101 was also induced by laminar shear stress and cell cycle arrest at the
G1/S transition and suppressed endothelial cell proliferation via targeting mTOR [99].
MicroRNA-155 is upregulated by prolonged HSS in HUVECs and it modulated endothelium-
dependent vasorelaxation by repressing eNOS. Therefore, the inhibition of miR-155 improved
endothelial dysfunction during the development of atherosclerosis [100].
MicroRNA-21 and miR-92a were induced by both LSS and HSS. Compared with LSS-induced
miR-21, HSS-induced miR-21 decreased EC apoptosis and activated the NO pathway by
targeting PTEN [101]. As mentioned earlier, downregulation of miR-92a led to upregulation
of KLF2 and subsequent KLF2-mediated eNOS and TM, which facilitated the maintenance of
EC homeostasis and functions against inflammation and pro-atherosclerotic effects [94, 95].
4.3. Angiotensin II (AngII) and miRNAs
Angiotensin II (AngII) has been implicated in the development and progression of cardiovas‐
cular diseases such as hypertension, atherosclerosis, and restenosis after vascular injury [102].
AngII-mediated intracellular singling is activated through its G-protein-coupled AngII Type
1 receptor (AT1R). In both VSMCs and ECs, AngII leads to vascular and endothelial dysfunc‐
tions by generating intracellular reactive oxygen species (ROS) and negatively regulating NO
signaling pathway, respectively [103, 104]. Zhu et al. found that miR-155, miR-221, and
miR-222 were highly expressed in both HUVECs and VSMCs, and a key endothelial tran‐
scription factor for inflammation and tube formation Ets-1 was a putative target of miR-155,
miR-221, and miR-222 [105]. Interestingly, miR-155 also targeted AT1R, and AngII-stimulated
HUVECs upregulates Ets-1 and its downstream genes, including VCAM1, MCP1, and FLT1
[105]. These results indicated that miR-155, miR-221, and miR-222 act as negative regulators
to inflammatory response of ECs caused by AngII stimulation.
4.4. Oxidized low-density lipoprotein (oxLDL) and miRNAs
Oxidized low-density lipoprotein (oxLDL) induces EC death and dysfunction through the
activation of NF-κB and AP-1 pathways, and it also activates pro-inflammatory response
during the progression of atherosclerotic vascular diseases [2, 106]. Based on microarray and
qRT-PCR analysis with oxLDL-stimulated HUVECs, Qin et al. found that four miRNAs are
upregulating including miR-365 and miR-142-3p, whereas eleven miRNAs are downregulat‐
ing including miR-590-5p and miR-33a in microarray, which expression levels are validated
with qRT-PCR [107]. Using computational prediction algorithms (TargetScan, microRNA.org,
and MicroCosm v5), the gene ontology (GO) database (www.geneontology.org), and KEGG
pathway database (www.genome.ad.jp/kegg), the authors predicted and identified the
functions of miRNA-targeted genes. As a result, miR-365 has been reported to be involved in
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oxLDL-induced apoptosis of ECs by suppressing the anti-apoptotic protein Bcl-2 [107].
Therefore, the inhibition of miR-365 may reduce EC apoptosis and inhibit the pro-atherogenic
progression caused by oxLDL.
5. Macrophage
The accumulation and activation of macrophages within the vascular wall are a crucial event
in vascular remodeling and implicate the progression of atherogenesis, which is initiated by
inflammation, a rise in circulating LDL levels, and the accumulation of oxLDL in macrophages
[108, 109]. Inflammation triggers the recruitment and infiltration of monocytes and macro‐
phage in atherosclerotic lesions, continuously accumulating lipids and oxLDL [110]. The
macrophages respond to various inflammatory stimuli, which lead to the changes in expres‐
sion of many genes and several miRNAs, including miR-155, miR-125a, miR-146a, and
miR-146b [111, 112]. Although the microRNAs involved in oxLDL accumulation and inflam‐
matory response in macrophages are currently unclear, considering the role of miRNAs in
VSMCs and ECs during arterial remodeling, the idea of miRNAs that also contribute the
macrophage functions does not seem to be illogical (Figure 5) [2].
Figure 5. miRNAs in macrophages during vascular remodeling.
5.1. miR-155
The expression of miR-155 increased in human atherosclerotic lesions, but circulating miR-155
is known to be downregulated in patients with coronary artery diseases [113, 114]. During
vascular remodeling, miR-155 is expressed in VSMCs, ECs, as well as activated macrophages
[115]. The oxLDL and/or ESS promote the recruitment of monocytes into the arterial wall
through ECs and then monocytes are differentiated toward macrophages and dendritic cells
(DCs) [108]. MiR-155 is the most important miRNA in macrophage-mediated inflammation
[116], and its expression is increased by several Toll-like receptor (TLR) ligands via myeloid
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differentiation primary response gene (MyD88) and/or TIR-domain-containing adapter-
inducing interferon-β (TRIF)-dependent signaling in the inflammatory activation of macro‐
phages [117]. In addition, the lipopolysaccharide (LPS) is also known to induce miR-155 in
monocytes and DCs. LPS-induced miR-155 expression is mediated by the single-strand RNA-
binding protein KH-type splicing regulatory protein (KSRP) in bone marrow-derived macro‐
phages [118]. In activated primary human monocyte-derived DCs, LPS-induced upregulation
of miR-155 inhibited Toll-like receptor/interleukin-1 (TLR/IL-1) inflammatory pathway as well
as TAB2 (an adaptor in the TLR/IL-1 signaling cascade), attenuating IL-1β and inflammatory
signals [119]. Furthermore, oxLDL and cytokine IFN-γ induced the expression of miR-155 that
modulated the inflammatory response in macrophages by repressing BCL6, a negative
regulator of pro-inflammatory NF-κB signaling. The attenuation of BCL6 was correlated to
upregulation of chemokine CCL2, an activator of monocyte recruiting into atherosclerotic
plaques [120]. MicroRNA-155 also regulates TGF-β signaling in macrophages by targeting
SMAD2. Overexpression of miR-155 inhibited TGF-β induction of SMAD2 phosphorylation,
which repressed TGF-β-dependent transcription of cytokines, such as IL-1β [121].
On the other hand, a potent anti-inflammatory cytokine IL-10 inhibited LPS-induced miR-155
expression via STAT3-dependent manner, which led to upregulation of the target proteins of
miR-155 such as Src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP1) and anti-
inflammatory genes [122]. Moreover, LPS-activated PI3K/Akt1 pathway inhibited expressions
of miR-155 and pro-inflammatory mediators [123]. Paradoxically, a small number of studies
reported that miR-155 is also downregulated in oxLDL simulation and reduces lipid uptake
and accumulation in macrophages [120, 124]. Therefore, miR-155 in macrophages maintains
the balance between pro- and anti-inflammatory responses, which is influenced by the diseases
context or extracellular microenvironments.
5.2. miR-125a
Similar to miR-155, upregulation of miR-125a seems to decrease lipid accumulation by directly
targeting oxysterol-binding protein-like 9 (ORP9), but the functional role of miR-125a in
oxLDL-stimulated monocytes and macrophage still remains unclear [125]. MicroRNA-125a
has been reported to be upregulated through oxLDL in primary human monocytes, and
inhibition of miR-125a increased the secretion of IL-6, TNF-α, IL-2, and TGF-β, possibly due
to enhanced expression of scavenger receptors (LOX-1, CD68).
5.3. miR-146a and miR-146b
MicroRNA-146a/b is upregulated after stimulation with oxLDL in primary human monocytes
[125]. MiR-146a and -b are located on different chromosomes, and differ by two nucleotides.
Stimulation of TLR-2, 4, and 5 has been reported to induce miR-146a/b expressions in macro‐
phages through NF-κB activation [126]. The oxLDL-mediated suppression of miR-146a
promoted lipid uptake and cytokine release, most likely due to reduced suppression of TLR-4
(target of miR-146a) in macrophage [124]. Additionally, miR-146a and b are known to upre‐
gulated in human atherosclerotic plaques [127].
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6. Circulating miRNAs as biomarkers
In addition to the significance of miRNAs regulating gene expression at the intracellular
regions, some miRNAs have been discovered in the extracellular body fluids including serum/
plasma and bloodstream [128, 129]. Interestingly, the extracellular circulating miRNAs show
remarkably stable and resistant against ribonucleases, freezing, boiling, low or high pH, and
so on, which signifies that some protective mechanisms can countervail degradation [130–
132]. The mature miRNAs are released from intracellular to extracellular environment via the
complex with RNA-binding proteins such as Argonaute-2 (Ago2), binding to high-density
lipoprotein (HDL), and loading into microvesicle bodies such as microvesicles, exosomes, or
apoptotic bodies (Figure 6) [133–136].
Figure 6. The cellular release mechanisms of miRNAs.
Although the cellular origin and function of the circulating miRNAs remain uncertain, their
expression profiles are changed by fluid types and physiology or pathology conditions [137,
138]. The extraordinarily stable and tissue/diseases specific profiles of circulating miRNAs
have been considered as promising biomarkers for diagnosis of diseases [139, 140].
Several studies suggest that circulating miRNAs may be taken into the recipient cells and
regulate target gene expression [141–143]. In vascular diseases, a few studies showed that
circulating miRNAs modulate the function of ECs [144, 145]. Zhang et al. found that the
secretion of microvesicles containing miR-150 from human monocytic cells THP-1 is increased
in the plasma of patients with atherosclerosis. Secreted monocytic miR-150 is transported into
human microvascular endothelial cells (HMEC-1) and then promotes HMEC-1 migration via
downregulating the miR-150 target gene c-Myb [144]. Likewise, Zernecke et al. showed that
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EC-derived apoptotic bodies, containing miR-126, upregulates the production of CXC
chemokine CXCL12, which promotes the recruitment of Sca-1+ progenitor cells and reduces
the atherosclerotic lesion formation in ApoE–/– mice. These results suggest that circulating
miR-126 in apoptotic bodies may have protective potential against atherosclerosis [145].
7. Conclusion
Vascular remodeling encompasses a series of complex biological pathways and involves the
phenotype change of VSMCs, EC dysfunction, as well as macrophage activation. The alteration
of VSMCs, ECs, and macrophage cellular functions is related to the various extracellular
stimulus-dependent changes in transcriptional regulation, which is regulated by miRNAs.
Thus, the identification of stimuli-dependent vascular remodeling which affects miRNA
expression in different vascular cell types is imperative. The augmenting or inhibiting of the
expression levels of specific miRNAs may provide opportunity for the development of
miRNA-based therapeutic application to treating diverse vascular pathologies. In addition,
extracellular circulating miRNAs have been reported to be altered under specific pathologic
conditions, implicating their usage as biomarkers for specific diseases including cardiovascu‐
lar disease. Although there are unsolved issues of the efficiency and safety of using miRNAs
in diagnosis and therapy, accumulating evidence indicate that continuous research on the
functions and mechanisms of miRNAs and the identification of a network between miRNAs
and their targets is highly recommended and the results will expand our understanding of
vascular remodeling and diseases.
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